Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Arkadios Wealth Advisors

Arkadios Wealth Advisors lifted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,964 shares of the company’s stock after buying an additional 1,379 shares during the quarter. Arkadios Wealth Advisors owned approximately 0.06% of Amphastar Pharmaceuticals worth $1,038,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Boston Trust Walden Corp purchased a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $26,189,000. Millennium Management LLC lifted its holdings in Amphastar Pharmaceuticals by 84.6% in the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after purchasing an additional 338,653 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock worth $43,154,000 after purchasing an additional 280,390 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth $9,085,000. Finally, Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $10,804,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now directly owns 30,471 shares of the company’s stock, valued at $1,333,715.67. The trade was a 24.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Rong Zhou sold 7,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the sale, the executive vice president now directly owns 118,469 shares in the company, valued at $5,262,392.98. This represents a 5.58 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,533 shares of company stock worth $1,987,482. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Stock Up 0.1 %

AMPH stock opened at $35.70 on Monday. Amphastar Pharmaceuticals, Inc. has a one year low of $34.60 and a one year high of $56.88. The firm has a market cap of $1.72 billion, a PE ratio of 11.90, a PEG ratio of 1.12 and a beta of 0.82. The firm’s 50 day moving average price is $41.15 and its 200-day moving average price is $44.12. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Wall Street Analyst Weigh In

AMPH has been the subject of several research reports. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective for the company. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $60.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.